A salmonella-linked recall at Taylor Farms has pushed food safety from the back room of the supply chain to the front page. When a company producing 40% of salad kits in the US faces questions, attention quickly shifts to the tools and services that help prevent the next incident. This article explores 3 stocks exposed to this news and how their food testing and quality control solutions might matter for your portfolio decisions.

The stocks in the list below are just a starting sample, and the full screen on Simply Wall St surfaced 27 more food safety and testing companies with equally compelling narratives that are not covered here. To identify, compare, and analyze those higher conviction ideas directly, head into the Food Safety and Testing Companies screener.

Tristel (AIM:TSTL)

Tristel is a UK based infection prevention specialist that supplies disinfectants for hospital medical devices, environmental surfaces, and other professional settings. Most of its roughly £49.5 million revenue comes from Hospital Medical Device Decontamination at about £43.4 million, with smaller contributions from Environmental Surface Disinfection at about £4.3 million and Other Revenue at about £1.9 million. The company currently has a market cap of about £196.7 million.

For investors watching the Taylor Farms salmonella recall, Tristel sits in the middle of rising hygiene and compliance demands. The company focuses on high level disinfection products and traceability software that help healthcare and potentially food related customers meet stricter standards as regulators and customers scrutinize contamination risks more closely. Shares trade on a P/E slightly below the wider European medical equipment group and well below some peers, while earnings quality is described as high and returns on equity are strong. The flipside is an unstable dividend record and a relatively new leadership team, which could add some execution risk just as Tristel pushes further into international markets and scales its digital platform story.

Tristel’s high quality earnings and strong returns on equity are sitting next to an unstable dividend record and fresh leadership. Get the full picture from the 3 key rewards and 1 important warning sign

Build your own high quality returns shortlist

Tristel and the other two stocks in this list all surfaced from a single Simply Wall St screener, but the real value comes from tailoring filters to what matters most to you. Use our flexible Screener to mix metrics like valuation, balance sheet strength, dividends, and risks, or start with any of our ready made Investing Ideas.

Revvity (RVTY)

Revvity is a health sciences company that supplies instruments, reagents, software, and diagnostics used in genetic screening, infectious disease testing, and drug discovery across hospitals, labs, and pharma. It generates about US$1.5b from Diagnostics and roughly US$1.4b from Life Sciences tools and software. The company currently has a market cap of about US$12.8b.

The Taylor Farms salmonella recall highlights why food producers and regulators lean on companies like Revvity for rigorous testing and diagnostics. Revvity operates at the intersection of higher margin, recurring software and consumables, tools for AI enabled drug discovery, and expanding reproductive and newborn screening. At the same time, the stock trades on a rich P/E, earnings have recently declined, and management is reshaping the portfolio while dealing with regulatory and pricing pressures in markets such as China. That combination of quality diagnostics exposure, AI related growth potential, and execution risk may make Revvity worth a closer look for food safety focused investors.

Revvity sits at the intersection of high margin diagnostics, AI tools and rich P/E expectations, yet recent earnings pressure keeps many investors cautious. See how the analysis report for Revvity frames the real risk reward twist.

Stevanato Group (STVN)

Stevanato Group designs and manufactures drug containment, delivery systems, and diagnostic solutions used by biopharma and healthcare companies worldwide. Most of its roughly €1.1b revenue comes from the Biopharmaceutical and Diagnostic Solutions segment, with about €253 million from Engineering and a negative €118 million from adjustments and unallocated items. The stock has a market cap of about US$5.5b.

Stevanato Group is gaining attention as more therapies move toward biologics and self-injection, areas where its syringes, vials, and GLP-1 focused pen injectors are already winning new contracts. Recent results show high value solutions lifting revenue, while the divestiture of Balda C. Brewer and margin progress in Engineering point to a cleaner, more focused business. At the same time, investors need to weigh customer concentration, ongoing capex and a relatively new management team that is still proving itself. With analysts expecting faster earnings growth and food safety systems under a brighter spotlight after the Taylor Farms recall, this is a stock many readers may wish to research in more detail before making an investment decision.

Stevanato Group’s push into biologics and self injection pen systems has many investors focused on revenue, yet the earnings path and customer mix tell a more nuanced story. Get the full context from the analysis report for Stevanato Group

Seeking Alternatives Before Everyone Else?

Fresh stock ideas move fast. Some quietly build momentum, others are caught just before a breakout or start dropping off the radar. Review these while it matters and consider them early in your research process.

• Identify companies already building real traction in artificial intelligence by reviewing the curated 5 AI small caps. This can be a way to study potential opportunities before the crowd focuses on the next AI headline.
• Build a watchlist of income-oriented companies with the hand picked 4 dividend fortresses while yields and balance sheets appear attractive for investors with a long term focus.
• Explore companies involved in power infrastructure by scanning the focused 37 power grid technology and infrastructure stocks. This can highlight grid and hardware specialists that may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.